227 related articles for article (PubMed ID: 20360469)
1. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.
Clendening JW; Pandyra A; Li Z; Boutros PC; Martirosyan A; Lehner R; Jurisica I; Trudel S; Penn LZ
Blood; 2010 Jun; 115(23):4787-97. PubMed ID: 20360469
[TBL] [Abstract][Full Text] [Related]
2. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.
Pandyra A; Mullen PJ; Kalkat M; Yu R; Pong JT; Li Z; Trudel S; Lang KS; Minden MD; Schimmer AD; Penn LZ
Cancer Res; 2014 Sep; 74(17):4772-82. PubMed ID: 24994712
[TBL] [Abstract][Full Text] [Related]
3. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
4. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma.
Wong WW; Clendening JW; Martirosyan A; Boutros PC; Bros C; Khosravi F; Jurisica I; Stewart AK; Bergsagel PL; Penn LZ
Mol Cancer Ther; 2007 Jun; 6(6):1886-97. PubMed ID: 17575117
[TBL] [Abstract][Full Text] [Related]
5. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
6. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Pandyra AA; Mullen PJ; Goard CA; Ericson E; Sharma P; Kalkat M; Yu R; Pong JT; Brown KR; Hart T; Gebbia M; Lang KS; Giaever G; Nislow C; Moffat J; Penn LZ
Oncotarget; 2015 Sep; 6(29):26909-21. PubMed ID: 26353928
[TBL] [Abstract][Full Text] [Related]
8. Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathway.
Muller AL; Freed DH
Curr Mol Pharmacol; 2017; 10(1):6-12. PubMed ID: 26758946
[TBL] [Abstract][Full Text] [Related]
9. Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion.
Warita K; Warita T; Beckwitt CH; Schurdak ME; Vazquez A; Wells A; Oltvai ZN
Sci Rep; 2014 Dec; 4():7593. PubMed ID: 25534349
[TBL] [Abstract][Full Text] [Related]
10. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
11. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Mevalonate Pathway for Treating Esophageal Cancer.
Wong JVS; Fatehi Hassanabad A
J Gastrointest Cancer; 2021 Jun; 52(2):819-821. PubMed ID: 33931828
[TBL] [Abstract][Full Text] [Related]
13. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
[TBL] [Abstract][Full Text] [Related]
14. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Two Old Friends to Fight Cancer: Caffeine and Statins.
Stouth DW; Lebeau PF; Austin RC
Cancer Res; 2023 Jul; 83(13):2091-2092. PubMed ID: 37403629
[TBL] [Abstract][Full Text] [Related]
16. Mevalonate Cascade and its Regulation in Cholesterol Metabolism in Different Tissues in Health and Disease.
Hashemi M; Hoshyar R; Ande SR; Chen QM; Solomon C; Zuse A; Naderi M
Curr Mol Pharmacol; 2017; 10(1):13-26. PubMed ID: 26758949
[TBL] [Abstract][Full Text] [Related]
17. The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention.
Young RP; Hopkins RJ
Curr Mol Pharmacol; 2017; 10(1):46-59. PubMed ID: 26758944
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii.
Hedl M; Rodwell VW
Protein Sci; 2004 Jun; 13(6):1693-7. PubMed ID: 15152097
[TBL] [Abstract][Full Text] [Related]
19. Coenzyme Q10 and statin-related myopathy.
Drug Ther Bull; 2015 May; 53(5):54-6. PubMed ID: 25977402
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalonic acid: a novel marker of hydroxymethylglutaryl coenzyme A reductase inhibition by statins.
Waldron J; Webster C
Ann Clin Biochem; 2011 May; 48(Pt 3):223-32. PubMed ID: 21355014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
